

WHO GUIDELINES ON
USE OF MEDICALLY
IMPORTANT ANTIMICROBIALS
IN FOOD-PRODUCING ANIMALS



# WHO GUIDELINES ON USE OF MEDICALLY IMPORTANT ANTIMICROBIALS IN FOOD-PRODUCING ANIMALS



WHO guidelines on use of medically important antimicrobials in food-producing animals ISBN 978-92-4-155013-0

### © World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <a href="https://creativecommons.org/licenses/by-nc-sa/3.0/igo">https://creativecommons.org/licenses/by-nc-sa/3.0/igo</a>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** WHO guidelines on use of medically important antimicrobials in food-producing animals. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <a href="http://apps.who.int/iris">http://apps.who.int/iris</a>.

**Sales, rights and licensing.** To purchase WHO publications, see <a href="http://apps.who.int/bookorders">http://apps.who.int/bookorders</a>. To submit requests for commercial use and queries on rights and licensing, see <a href="http://www.who.int/about/licensing">http://www.who.int/about/licensing</a>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Design and layout: Blossoming.it

# CONTENTS

Acknowledgements	V
Overall coordination	V
Funding	V
Acronyms and abbreviations	vii
Glossary of terms	ix
Executive summary	xi
Background	I
Methods	9
Recommendations and best practice statements	13
Recommendation I: Overall antimicrobial use	14
Recommendation 2: Growth promotion use	16
Recommendation 3: Prevention use (in the absence of disease)	18
Recommendation(s) 4: Control and treatment use (in the presence of disease)	20
Best practice statement I	22
Best practice statement 2	22
Contributors and their role in the development of these guidelines	23
Dissemination and implementation of these guidelines	27
Research gaps	29
Updating these guidelines	31
References	33

Annex I. External experts and WHO staff involved in development of these guidelines	37
Annex 2. Summary and management of declared interests	43
Annex 3. Critical and important outcomes for decision-making	47
Annex 4. Summaries of systematic reviews including supplementary report	53
Annex 5. Summaries of the narrative literature reviews	59
Annex 6. Recommendations and summary of the judgments of the guideline development group of the criteria related to the strength of the	
recommendations for each intervention	65

### Web Annex A. Evidence base (WHO/NMH/FOS/FZD/I7.2; available at:

http://apps.who.int/iris/bitstream/I0665/25924I/I/WHO-NMH-FOS-FZD-I7.2-eng.pdf)

# Web Annex B. From evidence to recommendations (WHO/NHM/FOS/FZD/I7.3; available at:

http://apps.who.int/iris/bitstream/I0665/259242/I/WHO-NMH-FOS-FZD-I7.3-eng.pdf)

# **ACKNOWLEDGEMENTS**

The World Health Organization (WHO) would like to thank the many individuals who contributed to these guidelines, especially Hanan Balkhy, Peter Collignon, John Conly, Cindy Friedman, Aidan Hollis, Samuel Kariuki, Hyo-Sun Kwak, Scott McEwen, Gérard Moulin, Antoinette Ngandjio, Bernard Rollin, Flavia Rossi, and David Wallinga who served as members of the Guideline Development Group (GDG); Peter Collignon for serving as Chair at the first GDG meeting in October 2016; and to both Scott McEwen and Peter Collignon for serving as Co-Chairs at the second GDG meeting in March 2017. WHO appreciates the contribution of participants at the February 2016 guidelines scoping meeting, including members of the WHO Advisory Group of Integrated Surveillance for Antimicrobial Resistance (AGISAR).

Several groups and individuals gathered and presented evidence that the GDG considered in the development of these guidelines. Two research teams, one at Bond University in Australia, led by Chris Del Mar, and the other at the University of Calgary in Canada, led by William Ghali, conducted systematic reviews on the effects of restrictions on the use in food-producing animals of medically important antimicrobials on antimicrobial resistance in bacteria isolated from food-producing animals and humans. Hattie Webb conducted a narrative literature review on transfer of antimicrobial resistance determinants from food-producing animals to humans. Scott McEwen led a narrative literature review on the potential unintended consequences associated with restrictions on antimicrobial use in food-producing animals. Ellen Silbergeld

provided a narrative literature review on biological plausibility for associations between antimicrobial use in food-producing animals and increased risks of human exposures to, and infections by, antimicrobial-resistant zoonotic pathogens. John Conly and Mauricio Ferri served as Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodologists, and prepared the evidence profiles tables, summary-of-findings tables, narrative evidence summaries, and the outcomes and ratings questionnaire. Special thanks go to Frederick Angulo for providing technical supports to WHO secretariat throughout the development of these guidelines.

Additional thanks go to the external review group, which included Saeed Murie Al-Shahrani, Casey Barton Behravesh, Delia Grace, Dik Mevius, Paturkar Ashish Motiram, Hnin Thidar Myint, Langelihle Simela, Linda Tollefson, Jan L. M. Vaarten, Haruo Watanabe, and Khadija Id Sidi Yahia.

WHO also acknowledges the contributions of WHO Steering Group as well as contributions of Henk Jan Ormel from the Food and Agriculture Organization of the United Nations (FAO) and Elisabeth Erlacher-Vindel of the World Organisation for Animal Health (OIE), who served as special members of the WHO Steering Group.

Assistance and guidance was provided by Susan Norris of the secretariat of the WHO Guidelines Review Committee throughout the development and finalization of the guidelines.

<sup>&</sup>lt;sup>1</sup> A full list of contributors is included as Annex I. Annex 2 includes a summary of the declared interests and thier management.

## **Overall coordination**

The work to develop these guidelines was initiated by the Department of Food Safety and Zoonoses of the WHO under the

coordination of Awa Aidara-Kane, with the support of Yuki Minato.

# **Funding**

The Governments of Japan and the Netherlands provided financial support for this work. The views of the funding bodies did

not influence the development or content of these guidelines.

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5\_26172



